26
Views
8
CrossRef citations to date
0
Altmetric
Original Paper

Characterization of Leishmania chagasi DNA Topoisomerase II: a Potential Chemotherapeutic Target

, , , , &
Pages 826-829 | Received 17 Apr 2003, Accepted 10 Sep 2003, Published online: 08 Jul 2009

References

  • Pearson RD, Lareau SM, Jeronimo SM. Leishmaniasis at the end of the millennium. Curr Infect Dis Rep 1999; 1: 448–52.
  • Jerônimo SMB, Oliveira RM, Mackay S, Costa RM, Sweet J, Nascimento ET, et al. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans R Soc Trop Med Hyg 1994; 88: 386–8.
  • Sundar S. Drug resistance in India visceral leishmaniasis. Trop Med Int Health 2001; 6: 849–54.
  • Gellert M. DNA topoisomerases. Ann Rev Biochem 1981; 50: 879–910.
  • Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action and resistance to ciprofloxacin. Am J Med 1987; 82: 12–20.
  • Shapiro TA, Klein VA, Englund PT. Drug-promoted cleavage of kinetoplast DNA minicircles. Evidence for type II topoisomerase activity in trypanosome mitochondria. J Biol Chem 1989; 264: 4173–8.
  • Shapiro TA, Englund PT. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci USA 1990; 87: 950–4.
  • Shen LL, Kohlbrenner WE, Weigl D, Baranowski J. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem 1989; 264: 2973–8.
  • Werbovetz KA, Lehnert EK, Macdonald TL, Pearson RD. Cytotoxicity of acridine compounds for Leishmania promasti- gotes in vitro. Antimicrob Agents Chem 1992; 36: 495–7.
  • Werbovetz KA, Spoors PG, Pearson RD, Macdonald TL. Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol Biochem Parasitol 1994; 65: 1–10.
  • Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci U S A 2003; 24: 7539 44.
  • Slunt KM, Grace JM, Macdonald TL, Pearson RD. Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agent Chem 1996; 40: 706–9.
  • Gamage SA, Figgitt DP, Wojcik SL, Ralph RK, Ransijn A, Mauel J, et al. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1’-substituted 9- anilinoacridines. J Med Chem 1997; 40: 2634–42.
  • Cheesman SJ. The topoisomerases of protozoan parasites. Parasitol Today 2000; 16: 277–81.
  • Das A, Dasgupta A, Sharma S, Ghosh M, Sengupta T, Bandopadhyay S, Majumder HK. Characterization of the gene encoding type II DNA topoisomerase from Leishmania donovani. A key molecular target in antileishmanial therapy. Nucleic Acids Res 2001; 29: 1844–51.
  • Kelly JM. Isolation of DNA and RNA from Leishmania. Methods Mol Biol 1993; 21: 123–31.
  • Thompson JD, Higgins DG, Gibson TJ. CLUSTALW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673–80.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.